Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Covidien Gains Capnography Market Leader Oridion Via $300 Mil. Acquisition

This article was originally published in The Gray Sheet

Executive Summary

Newly acquired Oridion Microstream exhaled carbon dioxide measurement technology dovetails with Covidien’s pulse oximetry and other patient monitoring products.

You may also be interested in...



Device/Diagnostics Quarterly Deal Statistics, Q2 2012

Medical device company financing brought in $977 million, a decrease over Q1’s $1.1 billion. Device acquisition activity was up to $4.6 billion, yet only one deal surpassed the billion-dollar mark. With late-stage financing again leading, diagnostics funding together brought in $336 million, an 11% increase over Q1. For the first time since Q1 2011, the diagnostics M&A dollar total moved up instead of down, with $7 billion in acquisitions and five of the seven transactions topping $100 million.

News In Brief

Teleflex buys Semprus BioSciences. CDC pilots HIV testing at retail clinics. Covidien closes Oridion deal. More news briefs.

News In Brief

Smith & Nephew launches orthobiologics spinout. CMS proposes CED for wound care gel. More news briefs.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT031112

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel